ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Lung CancerInoperable Disease
Second Affiliated Hospital of Guangzhou Medical University90 enrolled1 locationNCT06483347
Recruiting
Phase 2
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Liver CancerAntibody
Second Affiliated Hospital of Guangzhou Medical University90 enrolled1 locationNCT06482801